Recent FDA approval of nirsevimab and clesrovimab have transformed RSV prevention in infants, prompting new recommendations from the CDC and AAP and replacing the long-standing role of palivizumab.
Amanda Zahn McPherson, PharmD
Advertisement
PharmD, professor of pediatrics at the University of Georgia College of Pharmacy
Articles by Amanda Zahn McPherson, PharmD
Advertisement
Latest Updated Articles
Evolving Strategies for RSV Prevention in InfantsPublished: September 29th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Axatilimab: A New Frontier for Steroid-Refractory Chronic GVHD
2
CHEST 2025: Exploring the Link Between GLP-1 Receptor Agonists, Type 2 Diabetes, and Asthma Risk
3
Immunization and Vigilance: Preventing Infections in T-Cell Modifying Therapies
4
What to Know About the Latest Pediatric Respiratory Infections
5
